Aberdeen Group plc boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 7.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 583,884 shares of the biotechnology company's stock after purchasing an additional 41,018 shares during the quarter. Aberdeen Group

Shares of Vericel Corporation (NASDAQ: VCEL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid®, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid.

Congress Asset Management Co. grew its holdings in shares of Vericel Corporation (NASDAQ: VCEL) by 11.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,664,578 shares of the biotechnology company's stock after purchasing an additional 169,971 shares during the period. Congress Asset Management

Intech Investment Management LLC decreased its stake in shares of Vericel Corporation (NASDAQ: VCEL) by 42.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,887 shares of the biotechnology company's stock after selling 23,142 shares during the

Vericel Corporation (VCEL) came out with quarterly earnings of $0.45 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.38 per share a year ago.

Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript

Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025.

Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among

Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript